64681-28-3

Upstream product

• 556-56-9 allyl iodid 
• 24558-77-8 3,4,5,6-tetra-O-benzyl inositol 
• 851770-80-4 1-O-allyl-3,4,5-tri-O-benzyl-2-O-(4-methoxybenzyl)-D-myo-inositol 
• 124684-95-3 1-O-allyl-2,3,4,5-tetra-O-benzyl-6-O-(2',3',4',6'-tetra-O-benzyl-α-D-mannopyranosyl)-L-myo-inositol 
• 98906-25-3 (±)-1,2-O-isopropylidene-3,6-di-O-benzyl-myo-inositol 
• 58706-20-0 (+/-)-3,6-di-O-benzyl-1,2:4,5-di-O-isopropylidene-myo-inositol 
• 111392-24-6 C₄₀H₄₄O₆ 
• 39698-23-2 1,2,3,4-tetra-O-benzyl-6-O-prop-1-enyl-myo-inositol 
• 10583-42-3 6-O-allyl-1,2,3,4-tetra-O-benzyl-myo-inositol 
• 111392-24-6 C₄₀H₄₄O₆ 
• 39698-23-2 1,2,3,4-tetra-O-benzyl-5-O-prop-1-enyl-myo-inositol 
• 10583-42-3 5-O-allyl-1,2,3,4-tetra-O-benzyl-myo-inositol 
• 98906-26-4 (3aR,4R,5S,6S,7R,7aS)-5,6-Bis-allyloxy-4,7-bis-benzyloxy-2,2-dimethyl-hexahydro-benzo[1,3]dioxole 
• 98925-52-1 (+/-)-5,6-di-O-allyl-1,4-di-O-benzyl-myo-inositol 

Downstream Products

• 124684-93-1 Acetic acid (2R,3S,4S,5R,6R)-2-((1S,2S,3S,4R,5S,6R)-2-allyloxy-3,4,5,6-tetrakis-benzyloxy-cyclohexyloxy)-4,5-bis-benzyloxy-6-benzyloxymethyl-tetrahydro-pyran-3-yl ester 
• 124684-94-2 1-O-allyl-3,4,5,6-tetra-O-benzyl-2-O-(3',4',6'-tri-O-benzyl-α-D-mannopyranosyl)-D-myo-inositol 
• 124753-82-8 1-O-allyl-3,4,5,6-tetra-O-benzyl-2-O-(3',4',6'-tri-O-benzyl-α-D-mannopyranosyl)-L-myo-inositol 
• 108235-14-9 D,L-2,3,4,5,6-penta-O-benzyl-myo-inositol 1-(methanesulfonate) 
• 134275-56-2 myo-inositol 1-(-3,4-di-palmitoyloxybutyl)-sulfonate 
• 134275-56-2 myo-inositol 1-(-3,4-di-palmitoyloxybutyl)-sulfonate 
• 134275-53-9 2-(2,2-Dimethyl-[1,3]dioxolan-4-yl)-ethanesulfonic acid (1S,2R,3R,4S,5S,6R)-2,3,4,5,6-pentakis-benzyloxy-cyclohexyl ester 
• 134275-53-9 2-(2,2-Dimethyl-[1,3]dioxolan-4-yl)-ethanesulfonic acid (1S,2S,3R,4S,5S,6S)-2,3,4,5,6-pentakis-benzyloxy-cyclohexyl ester 
• 134275-54-0 3,4-Dihydroxy-butane-1-sulfonic acid (1S,2R,3R,4S,5S,6R)-2,3,4,5,6-pentakis-benzyloxy-cyclohexyl ester 
• 134275-54-0 3,4-Dihydroxy-butane-1-sulfonic acid (1S,2S,3R,4S,5S,6S)-2,3,4,5,6-pentakis-benzyloxy-cyclohexyl ester 
• 134275-55-1 Hexadecanoic acid 1-hexadecanoyloxymethyl-3-((1S,2R,3R,4S,5S,6R)-2,3,4,5,6-pentakis-benzyloxy-cyclohexyloxysulfonyl)-propyl ester 
• 10583-42-3 5-O-allyl-1,2,3,4-tetra-O-benzyl-myo-inositol 
• 39698-23-2 1,2,3,4-tetra-O-benzyl-5-O-prop-1-enyl-myo-inositol 
• 111392-24-6 C₄₀H₄₄O₆ 

Relevant academic research and scientific papers

The absolute configuration of (+)-1,2,4,5,6-penta-O-benzyl-myo-inositol

The absolute configuration of (+)-1,2,4,5,6-penta-O-benzyl-myo-inositol is correlated with 1D-1,4,5,6-tetra-O-benzyl-myo-inositol and thus confirmed as 1D-1,2,4,5,6-penta-O-benzyl-myo-inositol.

Defining the Interaction of Human Soluble Lectin ZG16p and Mycobacterial Phosphatidylinositol Mannosides

ZG16p is a soluble mammalian lectin that interacts with mannose and heparan sulfate. Here we describe detailed analysis of the interaction of human ZG16p with mycobacterial phosphatidylinositol mannosides (PIMs) by glycan microarray and NMR. Pathogen-rela

Glycerophosphoinositols: Total synthesis of the first fluorescent probe derivative

The first fluorescent glycerophosphoinositol probe was synthesized in moderate good yield (37%). The total synthesis applied a convergent synthetic strategy involving two successive coupling reactions between the three key moieties: myo-inositol, glycerol

Relative reactivity of hydroxyl groups in inositol derivatives: role of metal ion chelation

O-Alkylation of myo-inositol derivatives containing more than one hydroxyl group via their alkali metal alkoxides (sodium or lithium) preferentially occurs at a hydroxyl group having a vicinal cis-oxygen atom. In general the observed selectivity is relatively higher for lithium alkoxides than for the corresponding sodium alkoxide. The observed regioselectivity is also dependent on other factors such as the solvent and reaction temperature. A perusal of the results presented in this article as well as those available in the literature suggests that chelation of metal ions by inositol derivatives plays a significant role in the observed regioselectivity. Steric factors associated with the axial or equatorial disposition of the reacting hydroxyl groups do not contribute much to the outcome of these O-alkylation reactions. These results could serve as guidelines in planning synthetic strategies involving other carbohydrates and their derivatives.

New fluorescent probes reveal that flippase-mediated flip-flop of phosphatidylinositol across the endoplasmic reticulum membrane does not depend on the stereochemistry of the lipid

Glycerophospholipid flip-flop across biogenic membranes such as the endoplasmic reticulum (ER) is a fundamental feature of membrane biogenesis. Flip-flop requires the activity of specific membrane proteins called flippases. These proteins have yet to be i

Antagonists of myo-inositol 3,4,5,6-tetrakisphosphate allow repeated epithelial chloride secretion

Cystic fibrosis (CF) patients suffer from a defect in hydration of mucosal membranes due to mutations in the cystic fibrosis transmembrane regulator (CFTR), an apical chloride channel in mucosal epithelia. Disease expression in CF knockout mice is organ s

Synthetic approaches to heavily lipidated phosphoglyceroinositides

(Matrix presented) Naturally occurring phosphoinositide glycoconjugates are equipped with varied acyl residues that are important for their biological activity and biosynthesis. This paper reports that acylation at O2 of the myo-inositol moiety can be ach

Syntheses of penta-O-benzyl-myo-inositols, O-β-L-arabinosyl-(1 → 2)sn-myo-inositol, O-α-D-galactosyl-(1 → 3)-sn-myo-inositol, and O-α-D-galactosyl-(1 → 6)-O-α-D-galactosyl-(1 → 3)-sn-myo-inositol

Two-step conversions of myo-inositol into (±)-2,3,4,5,6- and 1,3,4,5,6-penta-O-benzyl-myo-inositols are described. Starting from these monohydroxy derivatives of myo-inositol, O-β-L-arabinopyranosyl-(1→2)-sn-myo-inositol from Japanese green tea, Camellia sinensis, and O-α-D-galactopyranosyl-(1→3)-sn-myo-inositol (galactinol) as well as its homolog, O-α-D-galactopyranosyl-(1→6(II))-galactinol, were synthesized by way of the in situ activating glycosylation procedure.

Inositol polyphosphates and methods of using same

The present invention provides compositions that are cell permeable antagonists of inositol polyphosphates. In addition, the invention provides methods for enhancing chloride ion secretion from a cell by contacting the cells with cell permeable antagonists of inositol polyphosphates. The invention also provides methods for enhancing chloride ion secretion in an individual by administering cell permeable antagonists of inositol polyphosphates to the individual. The invention additionally provides methods for alleviating a sign or symptom associated with cystic fibrosis in an individual by administering a cell permeable antagonist of inositol polyphosphates to the individual. The invention also provides compositions that are cell permeable agonists of inositol polyphosphates. In addition, the invention provides methods for decreasing chloride ion secretion from a cell by contacting the cell with cell permeable agonists of inositol polyphosphates. The invention also provides methods for decreasing chloride ion secretion in an individual by administering cell permeable agonists of inositol polyphosphates to the individual. The invention additionally provides methods for alleviating a sign or symptom associated with secretory diarrhea in an individual by administering cell permeable agonists of inositol polyphosphates to the individual.

Ready routes to key myo-inositol component of GPIs employing microbial arene oxidation or Ferrier reaction

Microbial arene oxidation or Ferrier reaction of enol acetates provides versatile complementary routes that greatly facilitate preparation of inositol synthon(s) for GPI assembly.